Mark Cuban’s Cost Plus Drugs vs. Big Pharma: The Strategic War You Need to Be Modeling Right Now
Mark Cuban did not build a pharmacy. He built a mirror and pointed it at an industry that had never […]
May 2026
How Pharma Companies Track IND/NDA Dates to Win Global Patent Extensions
The difference between a blockbuster drug that earns another five years of protected revenue and one that faces generic competition
How Pharma Companies Track IND/NDA Dates to Win Global Patent Extensions Read Post »
How Pharma Companies Track IND/NDA Dates to Win Global Patent Extensions
The difference between a blockbuster drug that earns another five years of protected revenue and one that faces generic competition
How Pharma Companies Track IND/NDA Dates to Win Global Patent Extensions Read Post »
Cracking Complex Generics: The Bioequivalence Playbook That Gets ANDAs Approved
How inhalers, injectables, and drug-device combinations are reshaping generic drug strategy — and what it takes to win. Abbreviated New
Cracking Complex Generics: The Bioequivalence Playbook That Gets ANDAs Approved Read Post »
The Patent Clock: How to Find Pharma’s Best Talent Before They Know They’re Looking
Track drug development pipelines and patent filings to surface passive candidates six to eighteen months before your competitors do. When
The Patent Clock: How to Find Pharma’s Best Talent Before They Know They’re Looking Read Post »
What Pharma Patent Litigation Actually Costs (It’s Not the Legal Bills)
How drug companies, insurers, payers, and patients absorb billions in collateral damage that never appears on a litigation docket “The
What Pharma Patent Litigation Actually Costs (It’s Not the Legal Bills) Read Post »
Australia’s Drug Patent Clock: The Complete Guide to How Long Protection Actually Lasts
The Number Everyone Gets Wrong Twenty years. Ask any pharma executive or patent attorney how long a drug patent lasts
Australia’s Drug Patent Clock: The Complete Guide to How Long Protection Actually Lasts Read Post »
The Reformulation Playbook: How Pharma Uses 505(b)(2) to Lock In New Patents, Block Generics, and Reset Prices
The Mechanism Most Analysts Still Underestimate Every few years, a drug that has been off-patent for a decade reappears in
The Drug Patent Cliff: A Procurement Manager’s Sourcing Playbook
How to turn expiring blockbusters into budget wins — before your competitors do Patent cliffs don’t sneak up on anyone.
The Drug Patent Cliff: A Procurement Manager’s Sourcing Playbook Read Post »
